[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100490889":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":61,"collaborators":63,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":26,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Yale University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Empagliflozin or Placebo in Acute","EXPERIMENTAL","Acute phase: Participants will receive 25 mg empagliflozin once on Day 0 or Day 7. Participants receive empaglifozin or placebo on Day 0. On Day 7, they will be crossed over to the alternate treatment.",[13],"Drug: Empagliflozin 25 mg vs Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Empagliflozin in Chronic","ACTIVE_COMPARATOR","Chronic phase: On day 8, all participants will receive 10 mg empagliflozin 10 mg x 8 weeks",[19],"Drug: Empagliflozin 10 MG",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Empagliflozin 25 mg vs Placebo","Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Empagliflozin 10 MG","Chronic Study- Empagliflozin 10 mg for 8 weeks",[15],[32],{"name":33,"affiliation":5,"role":34},"Jeffrey Testani, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Veena Rao, PHD","CONTACT","203-737-3571","veena.s.rao@yale.edu",{"name":42,"role":38,"phone":39,"phoneExt":26,"email":43},"Kara Otis","kara.otis@yale.edu",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","New Haven","Connecticut","06510","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-72.92816,41.30815,{"lat":56,"lon":55},[59],{"name":60,"role":38,"phone":26,"phoneExt":26,"email":26},"Veena Rao, PhD",{"type":62,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[64],{"name":65,"class":66},"Boehringer Ingelheim","INDUSTRY","100490889","phase-4-effect-of-empagliflozin-on-peritoneal-and-kidney-function-in-end-stage-renal-disease-100490889",false,"NCT05671991","Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease","EMPA-PD","Inclusion Criteria\n\n1. Patients actively undergoing PD with a reliably functioning PD catheter\n2. Stable peritoneal dialysis prescription\n3. PD vintage \\> 3 months\n4. Age \\>18 years of age\n\nExclusion Criteria:\n\n1. History of type 1 diabetes, diabetic ketoacidosis, \"brittle\" diabetes or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 6 months\n2. Use of an SGLT2 inhibitor within the prior 30 days\n3. 1 or more episodes of peritonitis in the previous 6 months or active infection of the peritoneal dialysis catheter\n4. Anemia with hemoglobin \\\u003C8g\u002FdL\n5. Inability to give written informed consent or follow study protocol\n6. Contraindication to receiving loop diuretics","ALL","18 Years",{"count":77,"type":78},30,"ESTIMATED","INTERVENTIONAL",[81],"PHASE4","The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis.\n\nThis is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week \"pre post\" open label extension in all 30 patients where they will receive empagliflozin daily.",[84],"End Stage Renal Disease on Dialysis",[86],"Peritoneal dialysis","2026-05-18",{"date":89,"type":90},"2026-05-22","ACTUAL",{"date":92,"type":90},"2023-03-01",{"date":94,"type":78},"2026-12-31",{"name":5,"class":6},1]